Active, not recruitingPhase 2NCT05694871
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
Studying Dedifferentiated liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Intervention
- Palbociclib(drug)
- Enrollment
- 77 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States
- Mercy Cancer Center - Carmichael, Carmichael, California, United States
- Mercy San Juan Medical Center, Carmichael, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente Dublin, Dublin, California, United States
- Mercy Cancer Center - Elk Grove, Elk Grove, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- Fresno Cancer Center, Fresno, California, United States
- Kaiser Permanente-Fresno, Fresno, California, United States
- Mercy Cancer Center, Merced, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05694871 on ClinicalTrials.govOther trials for Dedifferentiated liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06498648Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06422806Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06389799A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)Lund University Hospital
- RECRUITINGPHASE1NCT05711615Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT05886634A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE3NCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaSarcoma Alliance for Research through Collaboration
- ACTIVE NOT RECRUITINGPHASE1NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaJonsson Comprehensive Cancer Center